Login to Your Account

Earnings Roundup

Friday, October 25, 2013

• Alexion Pharmaceuticals Inc., of Cheshire, Conn., posted higher-than-expected Soliris (eculizumab) sales of $400.4 million for the third quarter, up 36 percent year over year. Analyst estimates had predicted sales of $395 million. The company attributed the growth to steady additions of new patients with paroxysmal nocturnal hemoglobinuria and increasing numbers of new patients with atypical hemolytic uremic syndrome beginning Soliris treatment in the U.S. and Europe.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription